Since 2019, Dr. Susanne Grond is a Senior Clinical Research Scientist at Eli Lilly Regional Operations GmbH in Vienna, where she is responsible from medical affairs perspective for an oral JAK-inhibitor for the treatment of moderate to severe atopic dermatitis. She started her career at the Univerisity of Graz where she graduated in Biochemistry and Molecular Biomedicine. She then pursued a PhD in Molecular Enzymology, supervised by prof. Zechner, and afterwards a PostDoc in the group of Prof. Hämmerle. All her studies were focused on the research on epidermal skin barrier development with a focus on ichthyoses. Then, she left the academic world to enter Eli Lilly GmbH, where she started as a trainee, worked two years as a Medical Affairs Professional and reached the position she covers now.

Jeta Muja, PhD holds a master’s degree in Pharmacy from the University of Graz, as well as a PhD from the Medical University of Graz. During her studies, Jeta Muja expressed great interest both in science, particularly in the field of cell biology and biochemistry, and in pharmaceutical technology. Therefore, she decided to serve an internship at the Department of Biophysics, Medical University of Graz, as well as in a hospital pharmacy at the Klinikum Wels-Grieskirchen. In addition, she tried her hand at teaching as a student assistant at the Institute of Pharmaceutical Sciences, University of Graz. Right after obtaining the PhD degree, Jeta Muja accepted a postdoctoral position at the Division of Molecular Biology and Biochemistry. Shortly after, she opted for a career in pharma industry at GL Pharma in Lannach, where she currently works as a quality control expert.

Dr. Verena Rupp is a Medical Science Relation Manager for Rare Diseases at Pfizer since 2019, where she focuses on transthyretin amyloidosis and new gene therapy. She started her career at the Graz University of Technology, where she first navigated the world of Biochemistry and Molecular Biomedicine and graduated from her Master studies in 2012 with a project related to gene identification and characterization in rare diseases. Thereafter, she did her PhD (2012-2018) and PostDoc (2018-2019) at the Institute of Human Genetics of the Medical University of Graz under the supervision of Prof. Michael Speicher, working on rare tumors, iPSC, CRISPR/Cas9 and circulating tumor cells.

Cornelia Schweinzer, PhD started her university education at the University of Graz. After her Master of Science in Molecular Microbiology, she continued with a PhD at the Medical University of Graz within the PhD program “Molecular Medicine”. In addition to her studies, she also completed postgraduate certificates, such as the “Clinical Trial Specialist” at Medical University of Graz and “Marketing and Management” at BFI Vienna and “Social Media Management” at WIFI Graz. In 2020 she also started a Master study in Innovation Management. Before her current position at Institut Allergosan, she was employed at QPS Austria where she started as a Preclinical Research Assistant after her PhD. At QPS Austria, she also gained experience as Head of Translational Medicine Unit, as well as a Business Development Manager. At Allergosan, she is for example responsible for interdisciplinary project management, global marketing, as well as fostering business relations and monitoring.